Concentric Analgesics Inc. announced today that the clinical-stage biopharmaceutical company received Breakthrough Therapy designation from the U.S. Food and Drug Administration for CA-008 in post-surgical pain.
The U.S. Food and Drug Administration approved Kala Pharmaceuticals Inc.’s treatment for reducing inflammation and pain following an eye surgery.
Anthem Inc. partnered with Walmart Inc. to launch a program in January 2019 that will allow the health benefit company’s Medicare Advantage plan customers to purchase over-the-counter medications from the retailer’s stores and website.
EGP-437 demonstrated better clinical performance than vehicle control, but did not meet its co-primary endpoints.
The Australian Competition and Consumer Commission said the ACCC is taking local units of GlaxoSmithKline and Swiss healthcare company Novartis to court over false or misleading representations in the marketing of pain relief products.
Durect Corporation inked a development and commercialization deal with Sandoz AG, a division of Novartis AG, totaling around $293 million.
Only some doses of Trevena’s experimental opioid painkiller were found as effective as morphine in two late-stage studies, though the drug met its main study goals.
Women who take the pain reliever acetaminophen during pregnancy may be more likely to have children with behavior problems than those who do not.
An Australian court ordered Reckitt Benckiser to pull several of its Nurofen pain relief products from the market, saying on Monday the British firm had misled consumers by marketing identical products for different types of pain. The Federal Court ruled that the Nurofen Back Pain, Period Pain, Migraine Pain and Tension Headache products were […]
PARIS – After experimental multiple sclerosis drug vatelizumab failed to meet its primary endpoints in a mid-stage trial, Sanofi AG (SNY) said it has dropped plans to develop the drug with India-based Glenmark Pharmaceuticals. During a second-quarter results analysis with media members, Glenmark revealed that Sanofi was terminating the development agreement for vatelizumab, also […]